CY1109338T1 - Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων συσσωματωσης πρωτεϊνης - Google Patents

Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων συσσωματωσης πρωτεϊνης

Info

Publication number
CY1109338T1
CY1109338T1 CY20091100910T CY091100910T CY1109338T1 CY 1109338 T1 CY1109338 T1 CY 1109338T1 CY 20091100910 T CY20091100910 T CY 20091100910T CY 091100910 T CY091100910 T CY 091100910T CY 1109338 T1 CY1109338 T1 CY 1109338T1
Authority
CY
Cyprus
Prior art keywords
methods
disorders
diagnosis
prevention
treatment
Prior art date
Application number
CY20091100910T
Other languages
Greek (el)
English (en)
Inventor
Joanne Mclaurin
Original Assignee
Mclaurin , Joanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclaurin , Joanne filed Critical Mclaurin , Joanne
Publication of CY1109338T1 publication Critical patent/CY1109338T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
CY20091100910T 2003-02-27 2009-09-01 Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων συσσωματωσης πρωτεϊνης CY1109338T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45136303P 2003-02-27 2003-02-27
US52095803P 2003-11-17 2003-11-17
US52353403P 2003-11-19 2003-11-19
US10/787,621 US7521481B2 (en) 2003-02-27 2004-02-26 Methods of preventing, treating and diagnosing disorders of protein aggregation
EP04715226A EP1608350B1 (en) 2003-02-27 2004-02-27 Methods of preventing, treating and diagnosing disorders of protein aggregation

Publications (1)

Publication Number Publication Date
CY1109338T1 true CY1109338T1 (el) 2014-07-02

Family

ID=32931587

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100910T CY1109338T1 (el) 2003-02-27 2009-09-01 Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων συσσωματωσης πρωτεϊνης
CY20141100936T CY1115732T1 (el) 2003-02-27 2014-11-11 Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων της συσσωματωσης πρωτεϊνων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20141100936T CY1115732T1 (el) 2003-02-27 2014-11-11 Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων της συσσωματωσης πρωτεϊνων

Country Status (15)

Country Link
US (7) US7521481B2 (enExample)
EP (4) EP2823813A1 (enExample)
JP (4) JP4999453B2 (enExample)
AT (1) ATE432694T1 (enExample)
AU (2) AU2004216544B2 (enExample)
BR (1) BRPI0407910A (enExample)
CA (1) CA2516563C (enExample)
CY (2) CY1109338T1 (enExample)
DE (1) DE602004021362D1 (enExample)
DK (3) DK2311445T3 (enExample)
ES (3) ES2327521T3 (enExample)
IL (2) IL170476A (enExample)
PT (3) PT2153829E (enExample)
SI (3) SI2311445T1 (enExample)
WO (1) WO2004075882A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046334A2 (en) * 2002-11-19 2004-06-03 Board Of Trustees Operating Michigan State University Antioxidant and antimicrobial agents and methods of use thereof
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2530421C (en) 2003-06-27 2015-04-21 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
WO2005009291A2 (en) * 2003-07-23 2005-02-03 Synapse Biomedical, Inc. System and method for conditioning a diaphragm of a patient
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
ZA200704872B (en) * 2004-11-17 2008-12-31 Mclaurin Joanne Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
US20090170957A1 (en) * 2005-10-13 2009-07-02 Antonio Cruz Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
JP5249043B2 (ja) 2005-12-12 2013-07-31 エーシー イミューン ソシエテ アノニム 治療ワクチン
US20070197453A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
US8676323B2 (en) * 2006-03-09 2014-03-18 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
CA2644804A1 (en) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
CA2655632A1 (en) * 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research Inhibitors of a.beta. and synuclein aggregation
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
CA2670405A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008124931A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
EP2656839A1 (en) * 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
WO2008144578A1 (en) * 2007-05-17 2008-11-27 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
US8478412B2 (en) * 2007-10-30 2013-07-02 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
US20090131857A1 (en) * 2007-11-20 2009-05-21 Mark Geiger Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
US8450466B2 (en) * 2008-03-21 2013-05-28 The General Hosptial Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
CA2740124A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
GB0821994D0 (en) * 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
CN102498204B (zh) 2009-03-26 2015-02-04 德普伊新特斯产品有限责任公司 人脐带组织细胞作为用于阿尔茨海默病的疗法
US20100249073A1 (en) * 2009-03-27 2010-09-30 Robert Sabin Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein
EP2545023A4 (en) * 2010-02-15 2017-04-12 Abbvie Inc. Process for the preparation of scyllo-inositol
CA2814682C (en) 2010-10-13 2019-01-15 Elan Pharmaceuticals, Inc. Methods of synthesis of scyllitol and related compounds
JP5980790B2 (ja) 2010-11-05 2016-08-31 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン
CA2837926A1 (en) * 2011-06-03 2012-12-20 Susan ABUSHAKRA Scyllo - inositol for the treatment of behavioral and psychiatric disorders
KR101365711B1 (ko) * 2013-04-30 2014-02-21 재단법인 경북해양바이오산업연구원 효모로부터 분리된 신규한 생물학적 계면활성제
EP3161018A4 (en) 2014-06-25 2018-01-24 Rensselaer Polytechnic Institute Oxetane polymers and methods of preparation thereof
WO2016047823A1 (ko) * 2014-09-25 2016-03-31 영남대학교 산학협력단 장구채 추출물 또는 이로부터 분리된 보르네시톨을 유효성분으로 함유하는 세포 노화 억제용 조성물
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US20170354669A1 (en) * 2016-02-24 2017-12-14 The Trustees Of Columbia University In The City Of New York Disruption of the interaction between amyloid beta peptide and dietary lipids
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
WO2018191415A1 (en) 2017-04-11 2018-10-18 Colorado State University Research Foundation Functionalization of metal-organic frameworks
WO2019014348A1 (en) 2017-07-11 2019-01-17 Colorado State University Research Foundation CHITOSAN COMPOSITE MATERIAL AND METALLO-ORGANIC STRUCTURE
US11844846B2 (en) 2018-05-16 2023-12-19 Emory University Styrylbenzothiazole derivatives and uses in imaging methods
MX2021005213A (es) * 2018-11-02 2021-09-08 Nutrition 21 Llc Composiciones que contienen complejos de silicato de arginina estabilizado con inositol y inositol para mejorar funciones cognitivas en jugadores de videojuegos.
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
EP3789018A1 (en) * 2019-09-09 2021-03-10 Servicio Andaluz De Salud Composition and methods for enhancing or promoting the secretion of ghrelin to promote a healthy metabolic aging
IL294021A (en) 2019-12-16 2022-08-01 Nutrition 21 Llc Methods of production of arginine-silicate complexes
EP4084787A1 (en) * 2020-01-03 2022-11-09 Biosearch S.A. Composition for use in the treatment of cognitive disorders
EP4215200A4 (en) * 2020-09-17 2024-10-09 Resonac Corporation Autophagy activator
JP2025530588A (ja) * 2022-09-07 2025-09-16 エアジェン ファーマ リミテッド Ｓｃｙｌｌｏ－イノシトールとフラボンとの組み合わせ

Family Cites Families (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2088897A (en) * 1935-03-25 1937-08-03 Goss Printing Press Co Ltd Printing press
US2557381A (en) * 1946-08-09 1951-06-19 William C Huebner Multiple unit printing press
DE2234089C3 (de) * 1972-07-08 1975-01-23 Automatic Druckmaschinenfabrik Dr. W. Hinniger U. Soehne, 1000 Berlin Offset-Rollen-Rotationsdruckmaschine
GB1581233A (en) * 1976-06-02 1980-12-10 Drg Uk Ltd Printing press
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
DE3405663A1 (de) 1984-02-17 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung von scyllo-inosit
US5330979A (en) 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
US5407924A (en) 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US5545632A (en) 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3610107A1 (de) * 1986-03-26 1987-10-08 Voith Gmbh J M Stellvorrichtung zum verstellen einer walze
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5135923A (en) 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US4758420A (en) 1986-07-14 1988-07-19 The Dow Chemical Company Solvent extraction of polychlorinated organic compounds from porous materials
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
JPH067158Y2 (ja) 1987-03-18 1994-02-23 株式会社藤井合金製作所 配管端末の防水構造
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3808142A1 (de) * 1988-03-11 1989-09-21 Goebel Gmbh Maschf Lagereinrichtung
DE3814752C1 (enExample) * 1988-04-30 1989-08-31 J.M. Voith Gmbh, 7920 Heidenheim, De
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
JPH03102492A (ja) 1989-06-12 1991-04-26 Mitsui Eng & Shipbuild Co Ltd 自動販売機のデータ送信システムおよび複合機能型自動販売機
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5111814A (en) * 1990-07-06 1992-05-12 Thomas Jefferson University Laryngeal pacemaker
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
JP2984043B2 (ja) 1990-09-18 1999-11-29 旭化成工業株式会社 ミオ・イノシトールデヒドロゲナーゼおよびその製造法
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
JPH05192163A (ja) 1991-09-30 1993-08-03 Suntory Ltd イノシトールデヒドロゲナーゼ遺伝子
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
JP3251976B2 (ja) 1992-06-23 2002-01-28 旭化成株式会社 ミオ・イノシトールデヒドロゲナーゼを生産する実質上純粋な微生物
US5351616A (en) * 1992-08-13 1994-10-04 Man Roland Druckmaschinen Ag Rotary web printing machine, particularly for printing on thick or carton-type stock webs with replaceable plate cylinders
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
NZ256610A (en) * 1992-10-05 1997-03-24 Virginia Tech Intell Prop Synthesis of epoxydiol intermediates in the preparation of inositols and inosose; epoxydiols
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
DK0619369T3 (da) * 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
ATE176779T1 (de) * 1993-08-11 1999-03-15 Hokko Chem Ind Co Verfahren zur herstellung von d-chiro inositol
US5412080A (en) 1993-08-25 1995-05-02 President And Fellow Of Harvard College Enterobactin compounds
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
DE4408025A1 (de) * 1994-03-10 1995-09-14 Koenig & Bauer Ag Druckwerk für eine Mehrfarbenrollenrotationsdruckmaschine
DE4430693B4 (de) * 1994-08-30 2005-12-22 Man Roland Druckmaschinen Ag Antriebe für eine Rollenrotations-Offsetdruckmaschine
US5550166A (en) 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP3630344B2 (ja) 1995-11-17 2005-03-16 北興化学工業株式会社 イノシトール立体異性体の製造方法
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
DK0966277T3 (da) 1997-03-10 2006-03-27 Univ Loma Linda Med Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
GB9801899D0 (en) 1998-01-29 1998-03-25 Univ London Neurotrophic properties of ipgs analogues
DE19805898C2 (de) * 1998-02-13 2003-09-18 Roland Man Druckmasch Druckwerk für eine Rollenrotationsdruckmaschine
US6720190B1 (en) 1998-03-27 2004-04-13 Ole Hindsgaul Methods for screening compound libraries
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US6227110B1 (en) * 1998-06-23 2001-05-08 Heidelberger Druckmaschinen Ag Wet printing press with throw-off mechanism
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
AUPP589398A0 (en) 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
CA2343004A1 (en) 1998-09-24 2000-03-30 Pharmacia & Upjohn Company Alzheimer's disease secretase
AUPP675898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
GB2389182B (en) 1999-02-10 2004-02-04 Elan Pharm Inc Method of purifying b-secretase
NZ534876A (en) 1999-02-10 2006-02-24 Elan Pharm Inc Human beta-secretase enzyme, inhibitors and their compositions and uses
IL144781A0 (en) 1999-02-26 2002-06-30 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6864240B1 (en) 1999-06-15 2005-03-08 Elan Pharmaceuticals, Inc. Dipeptide inhibitors of β-secretase
JP2003502342A (ja) 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤
WO2001003680A2 (en) 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
DE19937805A1 (de) * 1999-08-10 2001-02-15 Roland Man Druckmasch Druckwerk
DE19937803A1 (de) * 1999-08-10 2001-02-15 Roland Man Druckmasch Druckwerk
DE19937796B4 (de) * 1999-08-10 2007-03-22 Man Roland Druckmaschinen Ag Druckwerk
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
JP2001163810A (ja) 1999-09-30 2001-06-19 Microbial Chem Res Found １ｄ−キロ−イノシトールの新規合成方法および中間体
JP2003511094A (ja) 1999-10-18 2003-03-25 マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション 無脂肪体重及び体力を増強するための食物補充物質
US7728043B2 (en) 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
CA2388750A1 (en) 1999-11-09 2001-05-17 James Edmund Audia .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
WO2001034571A1 (en) 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
DE19963944C1 (de) * 1999-12-31 2001-06-13 Koenig & Bauer Ag Verfahren zum Einstellen einer Walze einer Druckmaschine
EP1254108A1 (en) 2000-01-24 2002-11-06 MERCK SHARP & DOHME LTD. Gamma-secretase inhibitors
DE10008215B4 (de) * 2000-02-23 2013-03-28 Manroland Web Systems Gmbh Druckwerk für eine Rotationsdruckmaschine mit Kreuzschlitten
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US20030144255A1 (en) * 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
JP2003528076A (ja) 2000-03-20 2003-09-24 メルク シャープ エンド ドーム リミテッド スルホンアミド置換架橋ビシクロアルキル誘導体
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
CA2406383A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US6716826B2 (en) 2000-05-12 2004-04-06 Rodaris Pharmaceuticals Limited Compounds and their uses
US6939857B2 (en) 2000-05-12 2005-09-06 Rodaris Pharmaceuticals Limited Compounds and their uses
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
GB0015627D0 (en) 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1299352B1 (en) 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
DE10031955A1 (de) 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6559891B1 (en) * 2000-08-15 2003-05-06 Sony Corporation Method and apparatus to generate tri-level HDTV synchronization pulses
JP3880051B2 (ja) 2000-11-02 2007-02-14 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害剤としてのスルファミド
ATE406371T1 (de) 2000-11-02 2008-09-15 Us Gov Health & Human Serv Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung
WO2002055715A1 (fr) 2001-01-15 2002-07-18 Hokko Chemical Industry Co., Ltd. Adn codant pour une d-myo-inositol 1-épimérase
CA2437563C (en) 2001-02-06 2010-03-23 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
EP1233021A3 (en) 2001-02-20 2002-11-20 Pfizer Products Inc. An inhibitor of Beta amyloid cleavage enzyme
US20060079533A1 (en) 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
EP1393900B1 (de) * 2001-04-09 2014-03-12 Koenig & Bauer Aktiengesellschaft Druckmaschine
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
CA2448084A1 (en) 2001-05-22 2002-11-28 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
EP1990057A1 (en) 2001-05-22 2008-11-12 Merck & Co., Inc. Beta-secretase substrates and uses thereof
DE60226729D1 (de) 2001-06-01 2008-07-03 Elan Pharm Inc Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
US6684775B2 (en) * 2001-06-07 2004-02-03 Heidelberger Druckmaschinen Ag Printing unit with roll-away inkers
US20050130941A1 (en) 2001-06-08 2005-06-16 Heinrich Schostarez Methods of treating alzheimer's disease
US7361688B2 (en) 2001-06-11 2008-04-22 Elan Pharmaceuticals, Inc. Substituted aminoalcohols useful in treatment of Alzheimer's disease
MXPA03011466A (es) 2001-06-12 2004-07-01 Elan Pharm Inc Macrociclos utiles en tratamiento de enfermedades de alzheimer.
CA2450167A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
EP1395251A2 (en) 2001-06-13 2004-03-10 Elan Pharmaceuticals, Inc. Aminediols as agents for the treatment of alzheimer's disease
MXPA04000139A (es) 2001-06-25 2004-06-03 Pharmacia & Up John Company Uso de compuestos biciclo para tratar enfermedad de alzheimer.
JP3981597B2 (ja) 2001-06-25 2007-09-26 北興化学工業株式会社 シロ−イノソースの製造法及びシロ−イノシトールの製造法
US6982264B2 (en) 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
CA2453447A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
CA2453451A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Aminediols for the treatment of alzheimer's disease
BR0211118A (pt) 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6599891B2 (en) 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
EP1411944A1 (en) 2001-08-03 2004-04-28 Schering Corporation Sulfonamide derivatives as gamma secretase inhibitors
PL372212A1 (en) 2001-08-03 2005-07-11 Schering Corporation Novel gamma secretase inhibitors
US20040266871A1 (en) 2001-08-28 2004-12-30 Schostarez Heinrich Josef Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
DE10145322A1 (de) * 2001-09-14 2003-04-03 Ina Schaeffler Kg Lageranordnung für Zylinder, Walzen oder Trommeln
MXPA04002785A (es) 2001-09-24 2004-07-29 Elan Pharm Inc Aminas sustituidas para tratamiento de enfermedad de alzheimer.
MXPA04003245A (es) 2001-10-04 2004-08-11 Elan Pharm Inc Hidroxipropilaminas.
WO2003030886A2 (en) 2001-10-05 2003-04-17 Elan Pharmaceuticals, Inc Allylamides useful in the treatment of alzheimer's disease
JP4547152B2 (ja) 2001-10-23 2010-09-22 オクラホマ メディカル リサーチ ファウンデーション β−セクレターゼ阻害剤および使用方法
CA2465316A1 (en) 2001-10-29 2003-05-08 James P. Beck Hydroxy substituted amides for the treatment of alzheimer's disease
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
NZ533158A (en) 2001-11-19 2006-09-29 Elan Pharm Inc 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines
MXPA04004903A (es) 2001-11-21 2005-06-06 Elan Pharm Inc Derivados de aminoacido utiles para el tratamiento de la enfermedad de alzheimer.
WO2003047576A1 (en) 2001-12-04 2003-06-12 Elan Pharmaceuticals, Inc. Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
BR0214736A (pt) 2001-12-06 2004-11-23 Elan Pharm Inc Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
CH698246B1 (de) 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
BR0306724A (pt) 2002-01-04 2006-04-11 Elan Pharm Inc carboxamidas amino substituìdas para tratamento de doença de alzheimer
EP1469810A4 (en) 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
EP1467729A1 (en) 2002-01-18 2004-10-20 The Genetics Company Inc. Beta-secretase inhibitors
US7053220B2 (en) 2002-02-01 2006-05-30 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
ATE448242T1 (de) 2002-04-24 2009-11-15 Hiroshi Mori Gamma-sekretase-inhibitoren
ATE435219T1 (de) 2002-05-01 2009-07-15 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
US6974829B2 (en) 2002-05-07 2005-12-13 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
DE10223666B4 (de) * 2002-05-28 2006-06-14 Windmöller & Hölscher Kg Farbwerksaufbau bei Flexodruckmaschinen
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20060089355A1 (en) 2002-06-11 2006-04-27 Michel Maillard Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
US20060154926A1 (en) 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
AU2003247758A1 (en) 2002-06-27 2004-01-19 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
WO2004022523A2 (en) 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
BR0314714A (pt) 2002-09-27 2005-08-02 Elan Pharm Inc Compostos para o tratamento da doença de alzheimer
US7243510B2 (en) 2002-09-30 2007-07-17 Bp Corporation North America Inc. Reduced carbon dioxide emission system and method for providing power for refrigerant compression and electrical power for a light hydrocarbon gas liquefaction process
AU2003279728B2 (en) 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
JP2006503102A (ja) 2002-10-17 2006-01-26 ジンギュ リァン 糖尿病の予防および治療のための天然化合物、その調製方法、およびその薬物的使用。
WO2004050609A1 (en) 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
JP2006510662A (ja) 2002-12-11 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療
FR2848452B1 (fr) 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP4662914B2 (ja) 2003-02-04 2011-03-30 エフ．ホフマン−ラ ロシュ アーゲー ガンマ−セクレターゼ阻害剤としてのマロンアミド誘導体
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
TW200505418A (en) 2003-04-21 2005-02-16 Elan Pharm Inc Phenacyl 2-hydroxy-3-diaminoalkanes
AR044044A1 (es) 2003-04-21 2005-08-24 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida
TW200510405A (en) 2003-05-13 2005-03-16 Schering Corp Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
MXPA05012323A (es) 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
US7060698B2 (en) 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
EP2511267A1 (en) 2003-06-05 2012-10-17 Elan Pharmaceuticals Inc. 3-((n-acylated aminoacyl)amino)pyrazoles as inhibitors of beta-amyloid peptide production useful for the treatment of alzheimer's disease
CN100430377C (zh) 2003-06-30 2008-11-05 麦克公司 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂
CN1909897A (zh) 2003-07-01 2007-02-07 默克公司 用于治疗阿尔茨海默病的苯基羧化物β－分泌酶抑制剂
EP1671129A1 (en) 2003-07-21 2006-06-21 Angiogenetics Sweden AB Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
JP4448134B2 (ja) 2003-08-08 2010-04-07 シェーリング コーポレイション ベンズアミド置換基を有する環状アミンｂａｓｅ−１阻害剤
JP2007502278A (ja) 2003-08-14 2007-02-08 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のための大員環β−セクレターゼ阻害剤
CA2539042A1 (en) 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
ATE396973T1 (de) 2003-10-03 2008-06-15 Merck & Co Inc Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
GB0323258D0 (en) 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
PL1673347T3 (pl) 2003-10-06 2016-01-29 Hoffmann La Roche Podstawione pochodne dibenzo-azepiny i benzo-diazepiny użyteczne jako inhibitory gamma-sekretazy
DK2058390T3 (da) 2003-10-14 2013-05-06 Hokko Chem Ind Co Fremgangsmåde til fremstilling af scyllo-inositol
US20050171112A1 (en) 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
DE602004011255T2 (de) 2003-11-11 2009-01-08 F. Hoffmann-La Roche Ag Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
CA2546142A1 (en) 2003-11-24 2005-06-09 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA06005734A (es) 2003-11-28 2006-08-17 Hoffmann La Roche Acidos tetronico y tetramico como inhibidores de beta-secretasa.
EP1697308B1 (en) 2003-12-19 2014-03-19 Merck Sharp & Dohme Corp. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
KR100803996B1 (ko) 2003-12-31 2008-02-18 포항공과대학교 산학협력단 아밀로이드 전구체 단백질 프로세싱 저해제
AU2004315399B2 (en) 2004-01-29 2009-08-06 Cellzome Ag Treatment of neurodegenerative diseases by the use of ATP7A-modulators
DK1713501T3 (da) 2004-01-29 2008-05-26 Cellzome Ag Behandling af neurodegenerative sygdomme ved anvendelse af GPR49
WO2005095326A2 (en) 2004-03-25 2005-10-13 Elan Pharmaceuticals, Inc. 2-amino- and 2-thio-substituted 1,3-diaminopropanes
US20070203147A1 (en) 2004-03-30 2007-08-30 Coburn Craig A 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors
KR20070010144A (ko) 2004-04-05 2007-01-22 쉐링 코포레이션 신규한 감마 세크레타제 억제제
EP1740581B1 (en) 2004-04-20 2012-08-22 Merck Sharp & Dohme Corp. 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CA2563615A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
CA2566053A1 (en) 2004-05-13 2005-12-01 Merck & Co., Inc. Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
US20060004096A1 (en) 2004-05-28 2006-01-05 Joseph Larner Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
JP4406327B2 (ja) 2004-06-29 2010-01-27 儀昭 新田 タイヤチップ製造装置
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
ZA200704872B (en) 2004-11-17 2008-12-31 Mclaurin Joanne Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
WO2006088705A1 (en) 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006112000A1 (ja) 2005-03-30 2006-10-26 The Niigata Institute Of Science And Technology 大腸菌変異株による２－デオキシ－シロ－イノソースの合成および精製する方法並びに得られた２－デオキシ－シロ－イノソース
KR20060105233A (ko) 2005-04-02 2006-10-11 삼성전자주식회사 하이브리드 디스크, 그 기록 및/또는 재생 장치 및 방법
WO2007002220A2 (en) 2005-06-21 2007-01-04 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as beta-secretase inhibitors
AU2006270084B2 (en) 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
US20090182021A1 (en) 2005-08-03 2009-07-16 Nanternet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
WO2007021793A1 (en) 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
US20090170957A1 (en) 2005-10-13 2009-07-02 Antonio Cruz Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
ATE502036T1 (de) 2005-10-25 2011-04-15 Janssen Pharmaceutica Nv Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4- düpyrimidinderivate
US20070197453A1 (en) 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
US20070197452A1 (en) 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
CA2579188A1 (en) 2006-02-17 2007-08-17 Joanne Mclaurin Treatment of amyloid-related diseases
CA2644804A1 (en) 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
CA2652238A1 (en) 2006-05-18 2007-11-29 Merck Frosst Canada Ltd. Phenanthrene derivatives as mpges-1 inhibitors
WO2007134449A1 (en) 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
EP1884531A1 (en) 2006-07-30 2008-02-06 Lonza Compounds GmbH & Co. KG Sheet molding compounds (smc) comprising thermosetting resins based on renewable resources
CA2697675A1 (en) 2006-08-25 2008-02-28 Allan Basbaum Intrathecal administration of triptan compositions to treat non-migraine pain
CN101511304A (zh) 2006-09-06 2009-08-19 奥尔特克斯公司 人工心脏瓣膜、系统和移植方法
WO2008034244A1 (en) 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
CA2670405A1 (en) 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
CN101686986A (zh) 2006-12-29 2010-03-31 诺尔姆奥克西斯公司 环多醇和其衍生物及其治疗应用
WO2008098371A1 (en) 2007-02-16 2008-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Compositions and method for reducing amyloid beta in a mammal
US20110105626A1 (en) 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20100331267A1 (en) 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
WO2008124931A1 (en) 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
EP2656839A1 (en) 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
JP5034916B2 (ja) 2007-12-10 2012-09-26 富士通セミコンダクター株式会社 性能評価モデル生成方法、システム性能評価方法、及び性能評価モデル生成装置
BRPI0912075A2 (pt) 2008-08-06 2017-05-23 Invista Technologies Sarl "artigo que compreende ao menos um substrato relativamente não elástico, um material de poliuretano selecionado a partir do grupo que consiste em um filme e um ou mais filamentos, processo para fabricar uma estrutura compósita elástica e processo para fabricar uma estrutura laminada compósita multicamada elástica"
CA2737163C (en) 2008-09-15 2019-03-12 Elan Pharmaceuticals, Inc. Methods of treatment of hyperuricemia and associated disease states
CA2740124A1 (en) 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
CA2837926A1 (en) 2011-06-03 2012-12-20 Susan ABUSHAKRA Scyllo - inositol for the treatment of behavioral and psychiatric disorders

Also Published As

Publication number Publication date
ES2520047T3 (es) 2014-11-11
AU2009251035B2 (en) 2012-12-13
JP4999453B2 (ja) 2012-08-15
EP2153829A1 (en) 2010-02-17
IL220065A (en) 2015-08-31
IL220065A0 (en) 2012-09-24
DK2311445T3 (da) 2014-06-16
DK1608350T3 (da) 2009-09-07
JP2016117743A (ja) 2016-06-30
US8859628B2 (en) 2014-10-14
US20150031776A1 (en) 2015-01-29
WO2004075882A1 (en) 2004-09-10
PT2153829E (pt) 2014-10-16
US20140073701A1 (en) 2014-03-13
BRPI0407910A (pt) 2006-02-14
PT2311445E (pt) 2014-06-25
AU2009251035A1 (en) 2010-01-14
JP2006522740A (ja) 2006-10-05
EP2823813A1 (en) 2015-01-14
EP2311445B1 (en) 2014-03-26
ES2475977T3 (es) 2014-07-11
ES2327521T3 (es) 2009-10-30
CA2516563C (en) 2013-08-20
AU2004216544A1 (en) 2004-09-10
US20040204387A1 (en) 2004-10-14
JP2014065731A (ja) 2014-04-17
AU2004216544B2 (en) 2009-09-24
ATE432694T1 (de) 2009-06-15
US20120157549A1 (en) 2012-06-21
JP2011105733A (ja) 2011-06-02
SI2311445T1 (sl) 2014-08-29
EP1608350B1 (en) 2009-06-03
SI1608350T1 (sl) 2009-12-31
DE602004021362D1 (de) 2009-07-16
IL170476A (en) 2013-05-30
US7521481B2 (en) 2009-04-21
DK2153829T3 (da) 2014-10-27
EP2311445A1 (en) 2011-04-20
SI2153829T1 (sl) 2014-12-31
US9833420B2 (en) 2017-12-05
US20070078099A1 (en) 2007-04-05
PT1608350E (pt) 2009-08-28
US20150164821A1 (en) 2015-06-18
US20090227686A1 (en) 2009-09-10
CA2516563A1 (en) 2004-09-10
EP1608350A1 (en) 2005-12-28
CY1115732T1 (el) 2017-01-25
EP2153829B1 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
CY1109338T1 (el) Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων συσσωματωσης πρωτεϊνης
WO2005020972A3 (en) Combination therapy for the treatment of ocular neovascular disorders
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
DE602004027888D1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihr
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
DE602004028920D1 (de) Per
DE602005025897D1 (de) Verfahren und zusammensetzungen in verbindung mit morbus alzheimer
ATE452652T1 (de) Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
CY1105880T1 (el) Χρηση μιας φαρμακευτικης συνθεσεως πepιεχουσης γαλακτικο οξυ ή γαλακτικη ριζα και καλιο για την αγωγη του εγκεφαλικου οιδηματος ή του τραυματισμου του εγκεφαλου
CY1110373T1 (el) Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων
WO2007087457A3 (en) Combination therapy for the treatment of neovascular disorders
PT1635799E (pt) Formulações farmacêuticas de compostos inibidores da proteína amilóide
BRPI0510501A (pt) antagonistas do receptor 3 de histamina
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
WO2005042561A3 (en) Neural regeneration peptides and methods of use
EP1614428A4 (en) MEDICAMENT FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES
DE602006019759D1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
CY1115261T1 (el) Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων της συσσωματωσης πρωτεϊνων
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
RU2003124971A (ru) Способ лечения больных с невротическими и соматоформными расстройствами
WO2004080535A3 (en) Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777